Texas Oncology-Baylor Sammons Cancer Center — Dallas, Texas

Texas Oncology-Baylor Sammons Cancer Center is a clinical research site located in Dallas, Texas, United States 75246.

Crixeo Clinical Trials Trust Score: 23/100 (FAILING). This profile has not yet been claimed by the site owner.

Texas Oncology-Baylor Sammons Cancer Center has participated in 28 clinical trials with 4 currently active.

Therapeutic areas: Urothelial Carcinoma, HER2 Positive Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms.

Sponsors: Genentech, Inc., Seagen Inc., Hoffmann-La Roche.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Dallas

Browse all research sites in Texas · View every site in Dallas

Sponsor Feasibility Report

Trust Score: 23/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Texas Oncology-Baylor Sammons Cancer Center?

Texas Oncology-Baylor Sammons Cancer Center has a Crixeo Trust Score of 23/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Texas Oncology-Baylor Sammons Cancer Center conducted?

Texas Oncology-Baylor Sammons Cancer Center has 28 clinical trials on record, with 4 currently active. Their work covers Urothelial Carcinoma, HER2 Positive Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms.

Is Texas Oncology-Baylor Sammons Cancer Center accredited by Crixeo Clinical Trials?

Texas Oncology-Baylor Sammons Cancer Center has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Texas Oncology-Baylor Sammons Cancer Center?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.